The MeCo Score™ is a first-in-class test that helps identify patients with early-stage breast cancer who have a poor prognosis [1] and may respond to FDA-approved antifibrotic therapy [2].
Additionally, the MeCo Score™ is associated with breast cancer progression via circulating tumor cells (CTCs) [3], an emerging surrogate for breast cancer prognosis and response to therapy.
The MeCo Score (TM) is an investigational assay that is not FDA approved or demonstrated to be safe or effective for any use.
[1] Watson, A.W. et al. (2021). Cell Reports. 29;35(13):109293. doi: 10.1016/j.celrep.2021.109293
[2] Data on file with the Spanish National Cancer Research Center (CNIO) and MeCo Diagnostics Holdings, Inc.
[3] Data on file with Cleveland Clinic and MeCo Diagnostics Holdings, Inc.
Copyright © 2022 MeCo Diagnostics Holdings, Inc. - All Rights Reserved.